Patents Assigned to Novartis Vaccines and Diagnostics, Inc.
  • Publication number: 20120122962
    Abstract: The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer.
    Type: Application
    Filed: March 30, 2011
    Publication date: May 17, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Jang HAN, Mi-Young SEO, Michael HOUGHTON
  • Patent number: 8178086
    Abstract: Methods for activating HCV-specific T cells are described. The methods utilize one or more administrations of HCV protein compositions, followed by one or more administrations of a viral vector comprising a nucleic acid encoding a least one HCV epitope that is present in the first composition. The protein compositions can further comprise an immunostimulatory nucleic acid and or other adjuvants and immune stimulatory compounds.
    Type: Grant
    Filed: January 4, 2007
    Date of Patent: May 15, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Michael Houghton, Yin-Ling Lin
  • Patent number: 8178493
    Abstract: The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis.
    Type: Grant
    Filed: April 6, 2009
    Date of Patent: May 15, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: David T. Hung, Brian H. Annex, Kevin P. Landolfo, W. Michael Kavanaugh
  • Publication number: 20120114693
    Abstract: Mucosal delivery of antigens using, for example, a replication-defective gene delivery vehicle, particularly replication-defective alphavirus vectors and particles, is described. Also described are compositions comprising a mucosal adjuvant and one or more antigens derived from HIV. Also provided is the use of these gene delivery vehicles in inducing mucosal, local, and/or systemic immune responses following mucosal immunization regimes.
    Type: Application
    Filed: January 12, 2012
    Publication date: May 10, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: MICHAEL VAJDY, JOHN POLO, THOMAS W. DUBENSKY, JR., DEREK O'HAGAN
  • Patent number: 8173363
    Abstract: The invention provides a method for generating a database of candidate essential genes in Staphylococcus aureus, as well as otherwise important genes that, when mutated, lead to a growth attenuated phenotype. Such genes and mutants of such genes are important for identifying antibacterial agents suitable for treating and preventing S. aureus infections. The invention includes methods for confirming the essentiality or importance of candidate genes, as well as methods for utilizing those genes to screen for new antibacterial drugs. The invention also includes the antibacterial agents identified using the disclosed methods, as well as methods of using the same for treating and preventing Staphylococcus infection.
    Type: Grant
    Filed: August 20, 2003
    Date of Patent: May 8, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Kim Folger Bruce, Paul Warrener, Jennifer McLarnan, Kevin Hou
  • Patent number: 8173375
    Abstract: Reagents, methods and immunodiagnostic test kits for the accurate detection of hepatitis B virus (HBV) infection are disclosed. The methods and kits employ novel rabbit monoclonal antibodies directed against HBV surface antigens (HBsAg) with mutations in the “a” determinant region of HBsAg.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: May 8, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: David Ying Chien, Yiu-Lian Fong, Azita Tabrizi, Heather Todd, Mark David VanCleve
  • Patent number: 8173137
    Abstract: The present disclosure relates to vectors comprising polynucleotide sequences that encode HIV polypeptides. In particular, the disclosure relates polycistronic vector constructs comprising sequences that encode HIV polypeptides as a single polyprotein. Compositions comprising these vectors and sequences along with methods of using these vectors and sequences are also disclosed.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: May 8, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Jan Zur Megede, Susan W. Barnett
  • Patent number: 8168194
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Grant
    Filed: February 3, 2006
    Date of Patent: May 1, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Susan Barnett, Rino Rappuoli, Victoria A. Sharma, Indresh K. Srivastava, Jan Zur Megede
  • Patent number: 8158418
    Abstract: Chimeric alphaviruses and alphavirus replicon particles are provided, including methods of making and using same. Specifically, alphavirus particles are provided having nucleic acid molecules derived from one or more alphaviruses and structural proteins (capsid and/or envelope) from at least two or more alphaviruses. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle, are disclosed.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: April 17, 2012
    Assignee: Novartis Vaccines & Diagnostics Inc.
    Inventors: John Polo, Silvia Perri, Kent Thudium
  • Patent number: 8153843
    Abstract: Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.
    Type: Grant
    Filed: September 21, 2009
    Date of Patent: April 10, 2012
    Assignees: University of Washington, Novartis Vaccines and Diagnostics, Inc.
    Inventors: Niels H. Andersen, Jason Bowman, Alice L. Erwin, Eric A. Harwood, Toni Kline, Khisimuzi E. Mdluli, Simon Ng, Keith B. Pfister, Ribhi Shawar, Allan S. Wagman, Asha Yabannavar
  • Patent number: 8142793
    Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: March 27, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
  • Patent number: 8138161
    Abstract: The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA (dsRNA) molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer. The invention provides modified RNA molecules that are modified to include a dsRNA or siRNA wherein one or more of the pyrimidines in the RNA molecule are modified to include 2?-Fluorine. The invention also provides dsRNA or siRNA in which all pyrimidines are modified to include a 2?-Fluorine. The invention provides that the 2?-Fluorine dsRNA or siRNA molecule is further modified to include a two base deoxynucleotide “TT” sequence at the 3? end of the molecule.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: March 20, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Jang Han, Michael Houghton
  • Patent number: 8137673
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Grant
    Filed: May 16, 2006
    Date of Patent: March 20, 2012
    Assignees: Novartis Vaccines and Diagnostics, Inc., J. Craig Venter Institute
    Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
  • Patent number: 8133494
    Abstract: The invention relates to polynucleotides encoding modified immunogenic HIV-1 South African subtype C Env polypeptides. The modifications to the Env polypeptides include deletions of V1, V2 and the stem region. The expression cassettes may be used, for example, to express the encoded polypeptide. A recombinant expression system for use in a selected host cell comprising an expression cassette encoding for the modified HIV-1 Env polypeptide is also described.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: March 13, 2012
    Assignee: Novartis Vaccine & Diagnostics Inc
    Inventors: Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse van Rensburg, Thomas J. Scriba
  • Patent number: 8124104
    Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: February 28, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
  • Patent number: 8119145
    Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: February 21, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
  • Patent number: 8105612
    Abstract: A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: January 31, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Marco Soriani, Isabella Santi
  • Publication number: 20120020977
    Abstract: The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.
    Type: Application
    Filed: October 4, 2011
    Publication date: January 26, 2012
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventor: Giulia KENNEDY
  • Patent number: 8101640
    Abstract: Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: January 24, 2012
    Assignees: Novartis Vaccines and Diagnostics, Inc., University of Washington
    Inventors: Niels H. Andersen, Jason Bowman, Alice Erwin, Eric Harwood, Toni Kline, Khisimuzi Mdluli, Simon Ng, Keith B. Pfister, Ribhi Shawar, Allan S. Wagman, Asha Yabannavar
  • Patent number: 8101349
    Abstract: The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.
    Type: Grant
    Filed: February 12, 2004
    Date of Patent: January 24, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Pablo Dominguez Garcia, Altaf Kassam, George Lamson